No headlines found.
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Globe Newswire (Wed, 8-May 4:01 PM ET)
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
Globe Newswire (Wed, 1-May 4:01 PM ET)
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Business Wire (Wed, 3-Apr 7:00 AM ET)
Business Wire (Tue, 2-Apr 4:01 PM ET)
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Lenz Therapeutics trades on the NASDAQ stock market under the symbol LENZ.
As of May 20, 2024, LENZ stock price climbed to $18.59 with 127,368 million shares trading.
LENZ has a market cap of $474.67 million. This is considered a Small Cap stock.
Last quarter Lenz Therapeutics reported $0 in Revenue and -$3.53 earnings per share. This met revenue expectation and missed earnings estimates by -$2.69.
The top ETF exchange traded funds that LENZ belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
LENZ support price is $15.63 and resistance is $17.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LENZ stock will trade within this expected range on the day.